Skip to main content

Advertisement

Table 1 Ongoing clinical trials in breast cancer brain metastases

From: Breast cancer brain metastases: the last frontier

Tumor subtype Treatment/target Experimental arm Control arm Clinicaltrials.gov ID/phase
All Chemotherapy Cabazitaxel None NCT02166658
Phase II
TPI 287 None NCT01332630
Phase II
ANG1005 None NCT02048059
Phase II
ANG1005 + trastuzumab (if HER2-positive) None NCT01480583
Phase II
Liposomal cytarabine + high-dose methotrexate None NCT00992602
Phase II
VEGF Bevacizumab + carboplatin + trastuzumab (if HER2-positive) None NCT01004172
Phase II
Bevacizumab + etoposide + cisplatin followed by WBRT WBRT alone NCT02185352
Phase II
Sorafenib + WBRT None NCT01724606
Phase I
Cabozantinib + trastuzumab (if HER2-positive) None NCT02260531
Phase II
Radiation WBRT + temozolamide None NCT02133677
Phase II
WBRT with hippocampal avoidance Conventional WBRT NCT01942980
Phase III
WBRT + efaproxiral + oxygen WBRT + oxygen NCT00083304
Phase III
HER2-positive Chemotherapy Cabazitaxel + lapatinib None NCT01934894
Phase II
HER2 Lapatinib + WBRT WBRT alone NCT01622868
Phase II
Neratinib ± capecitabine None NCT01494662
Phase II
Afatinib ± vinorelbine Investigator’s choice NCT01441596
Phase II
T-DM1 + WBRT None NCT02135159
Phase I
ARRY-380 + trastuzumab None NCT01921335
Phase I
mTOR Everolimus + trastuzumab + vinorelbine None NCT01305941
Phase II
Everolimus + lapatinib + capecitabine None NCT01783756
Phase Ib/II
PI3K BKM120 + trastuzumab ± capecitabine None NCT01132664
Phase Ib/II
MET Tesevatinib + trastuzumab None NCT02154529
Phase Ib/IIa
Radiation PCI None NCT00916877
Phase I
PCI + taxane + trastuzumab Taxane + trastuzumab NCT00639366
Phase III
SRS + HER2 directed therapy None NCT01924351
Phase II
Triple-negative PI3K BKM120 + capecitabine None NCT02000882
Phase II
PARP Iniparib + irinotecan None NCT01173497
Phase II
Radiation PCI Observation NCT02448576
Phase III
Hormone receptor-positive CDK4/6 Abemaciclib None NCT02308020
Phase II
  1. CDK cyclin-dependent kinase, HER2 human epidermal growth factor receptor 2, mTOR mammalian target of rapamycin, PARP poly ADP ribose polymerase, PCI prophylactic cranial irradiation, PI3K phosphatidylinositol 3-kinase, SRS stereotactic radiosurgery, VEGF vascular endothelial growth factor, WBRT whole-brain radiation therapy